RGCC Onconomics is a test useful for designing personalized treatment plans for each patient. The test assesses the efficacy of 110+ plus anti-cancer and also incorporates genetic profiling of 80 Plus cancer-related genes, providing insights into how gene expressions and physiological characteristics manifest the cancer.
RGCC Onconomics assesses the sensitivity of Anti-cancer drugs like cytotoxic agents, epothilones, nucleus spindle stabilizers, topoisomerase inhibitors, monoclonal antibodies, small molecular weight molecules, and resistance factors. The epigenetic analysis to determine if genes linked to cancer are over-expressed or downregulated, this information helps to optimize the timing and rotation of treatment regimens to manage cancer cell resistance.
The Onconomics test employs a dual approach, combining molecular and cellular methods to assess the effectiveness of 90+ chemotherapeutic agents and targeted therapies on your cancer cells.
The test applies to all types of cancer and not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
Now, the Circulating Tumour Cells (CTCs) and these Circulating Tumour Cells are grown in the lab and tested against anti-cancer drugs for efficacy (Similar to urine culture for urinary tract infection). Research Genetic Cancer Center (RGCC) in Greece conducts this test. Just by taking a 10ml blood sample, the most effective anti-cancer medicine can be given to patients. In the future, there will not be Breast Oncologists, Musculoskeletal Oncologists, or Head and Neck Oncologists. Only Gene-based Cancer Treatment. The future of oncology is tailor-made Gene-Based Cancer treatment.
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
The RGCC Onconomics test is advised for patients who are planning or currently undergoing chemotherapy, especially for those who haven’t shown improvement with initial or subsequent treatments. It’s suitable for those experiencing regular relapse/recurrence, newly diagnosed individuals, cases where the disease is rapidly advancing, or refractory cases with systemic disease.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Seeking comprehensive insights into your cancer journey? RGCC Onconomics test provides comprehensive guidance to navigate your battle against cancer. Gain clarity and direction in your treatment path with personalized insights tailored to your unique needs.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.